Pexa Group's Regulatory Pricing Scare Meets an All-Time-Low Valuation

A draft recommendation to cut prices 20% hit the stock hard, but management's competing asset-base calculation and director buying suggest the worst may be priced in.

31 Aug 2026 · 3 min read

Pexa Group fell more than 50 percent from around $15.58 to $7.31 through 2026 as a regulatory pricing review by NSW's IPART repeatedly delivered worse than expected news, culminating in a draft recommendation to cut prices by around 20 percent from mid-2027, even as fund managers argue the worst-case outcome is now priced in and directors are buying stock at an all-time-low valuation.

A long-running interoperability threat resolved, then a new one appears

Lakehouse Capital said Pexa was its heaviest detractor in April, falling 17.5 percent as regulatory concerns again took centre stage, even though ARNECC formally confirmed it would not proceed with a long-running interoperability program that independent reviews had found costly, complex and carrying meaningful execution risk, removing one overhang just as another appeared. Perennial Partners said the stock weakened after the Independent Pricing and Regulatory Tribunal released a consultation paper outlining a proposed methodology for reviewing Pexa's pricing model, with the market concerned the review could ultimately affect Australian pricing. Blackwattle Investment Partners detailed IPART's proposed framework, which would regulate the fees electronic property settlement providers like Pexa can charge based on an Initial Asset Base. Yarra Capital Management said the stock underperformed on the same news, cautioning that while only a methodology paper, the proposal to apply a regulated building blocks return model against that asset base carries real financial risk.

The draft recommendation lands worse than feared

Pendal Group said the stock fell 16.4 percent after IPART released a draft report recommending Pexa's prices be cut by around 20 percent, a $70 million revenue hit, from 1 July 2027, greater than the market had assumed ahead of the report, which had priced in a cut closer to 10 percent. Pendal called it a poor outcome given the very high fixed cost leverage in Pexa's Australian e-conveyancing exchange, though the final recommendation remains subject to submissions. Perennial Partners said the stock fell 28 percent in July as the draft review's proposed reduction in Pexa Exchange's regulated revenue requirement created near-term earnings uncertainty, compounded by softer housing transaction volumes and broader weakness across housing-exposed companies.

IPART released a draft report recommending PXA prices are cut ~20% (-$70 million revenue) from 1 July 2027, which was greater than the market had assumed ahead of the report. This is a poor outcome due to the very high fixed cost leverage in the Australia e-conveyancing exchange.

— Pendal Group, Newsletter, July 2026

Management pushes back, and the market may be overreacting

Seneca Financial Solutions rated the stock a buy, noting it sold off heavily on the IPART review, but management has submitted its own asset-base calculation that differs materially from the regulator's, with Seneca expecting the eventual outcome to land somewhere between the two. At an all-time-low valuation of around 11 times enterprise value to EBITDA, with directors buying on market, Seneca sees the worst-case scenario as already priced in, effectively offering the Australian monopoly cheaply alongside additional UK growth optionality.

Management has submitted its own asset-base calculation, which differs materially from the regulator's, and the fund expects an outcome somewhere between the two. At an all-time-low ~11x EV/EBITDA, with directors buying on market, the fund sees the worst as priced in.

— Seneca Financial Solutions, Presentation, August 2026

What fund managers say they are watching next is the final IPART pricing determination, which Seneca expects to land between the regulator's and management's competing asset-base calculations, housing transaction volume trends, and whether Pexa's UK expansion provides upside optionality the market is not currently pricing given the stock's depressed valuation.